The information contained herein is provided for educational purposes only and is not intended to constitute medical advice or replace discussions with a Healthcare Professional.All decisions regarding patient care must be made with a Healthcare Professional, considering the unique characteristics of the patient.
While every effort is made to update the information regularly and to offer the most current, correct and clearly expressed information possible, Pfizer cannot be held responsible for any inaccuracy, errors, omissions or misinterpretations.
Pfizer, its officers and/or its employees do not accept or take any responsibility whatsoever for any loss, whether direct, indirect or consequential, which may arise from reliance on information contained on these pages and actions resulting therefrom.Any liability that would or could arise as a result of the contents of these pages is hereby excluded to the fullest extent allowed by law.
No warranty is given that any files, downloads or applications available via this web site are free of viruses which have the ability to corrupt your system.
Any and all information is subject to change without notice.
The information provided in this site is intended only for appropriate Healthcare Professionals residing in SouthAfrica.
WEBINAR SESSION TIME
Wednesday, 15th May 2024
18:00 – 18:45pm
18:00 – 18:45pm
CDK 4/6 inhibitors: Addressing
CDK 4/6 inhibitors in HR+ HER2-
ABC Management
CDK 4/6 inhibitors in HR+ HER2-
ABC Management
Wednesday, 22nd May 2024
18:00 – 18:45pm
18:00 – 18:45pm
Navigation of NSCLC ALK
mutated lung cancer management
mutated lung cancer management
Wednesday, 29th May 2024
18:00 – 18:45pm
18:00 – 18:45pm
Therapeutic sequencing in
mRCC: Clinical Characteristics
driving Treatment Choice
mRCC: Clinical Characteristics
driving Treatment Choice
SPEAKERS
Wednesday, 15 th May 2024
Wednesday, 22 nd May 2024
Wednesday, 29 th May 2024
SCHEDULE
Wednesday, 15 th May 2024
Wednesday, 22 nd May 2024
Wednesday, 29 th May 2024
Time
Topic
Speaker
18:00 – 18:05
Welcome and Introductions
Pfizer Medical
18:05 – 18:35
CDK 4/6 inhibitors: Addressing CDK 4/6 inhibitors in
HR+ HER2- ABC Management
HR+ HER2- ABC Management
Speaker: Dr R Pienaar
18:35 – 18:45
Q&A & Close
Pfizer Medical
Time
Topic
Speaker
18:00 – 18:05
Welcome and Introductions
Pfizer Medical
18:05 – 18:35
Navigation of NSCLC ALK mutated lung cancer
management
management
Speaker: Dr S Chan
18:35 – 18:45
Q&A & Close
Pfizer Medical
Time
Topic
Speaker
18:00 – 18:05
Welcome and Introductions
Pfizer Medical
18:05 – 18:35
Therapeutic sequencing in mRCC:
Clinical Characteristics driving Treatment Choice
Clinical Characteristics driving Treatment Choice
Speaker: Prof S Mutambirwa
18:35 – 18:45
Q&A & Close
Pfizer Medical